This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2010
<p>Crohn disease (CD) is a progressive, inflammatory bowel disease that can occur in any part of the digestive tract. While CD affects people of all ages, approximately 25% to 30% of all CD patients develop symptoms before the age of 20 years. In the United States, approximately 100,000 to 150,000 children aged = 17 years have CD, and the incidence of pediatric CD appears to be increasing. The cause of pediatric CD remains unclear, but it is thought to be a complex interaction among environmental, genetic, and immunoregulatory factors. There is no known cure for CD. Treatment may include medication, nutrition supplements, surgery, or a combination of these options. Tumor necrosis factor-alpha (TNF-a) is an inflammatory protein that is part of the body's natural inflammatory and immune response, but when produced in excess, plays a key role in the inflammatory responses of some autoimmune diseases. Increased levels of TNF-a have been found in stool, urine, and mucosal biopsy specimens from patients with active CD. Thus, targeted therapy against TNF-a has become a logical therapeutic option for patients with CD.</p>
This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly.
Subject indexing assigned by CRD
Anti-Inflammatory Agents; Antibodies, Monoclonal; Child; Crohn Diseases
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: firstname.lastname@example.org
Date abstract record published